Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Adult Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
The purpose of the CSEG101A2202 study is to characterize the PK and PD of SEG101 at 5 mg/kg and to evaluate the safety and efficacy of SEG101. Study CSEG101A2202 is designed as a Phase II, multicenter, open-label study. Up to 45 patients (to identify 27 evaluable patients) will be enrolled to the treatment group crizanlizumab 5.0 mg/kg to complete full PK/PD sampling at week 1 and week 15. In all patients, trough PK/PD samples will also be collected prior to each dose. In addition, throughout the study (and when possible), all patients will have blood drawn for serum to assess PK and PD drawn at times of onset and resolution of each VOC event, fever, or suspected infection. Once the up to 45 patients are enrolled, 10 additional patients will be enrolled to the exploratory treatment group and begin at 7.5 mg/kg of crizanlizumab.
- Sickle Cell Disease
- Eligible Ages
- Between 18 Years and 70 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Male and non-pregnant female patients 18-70 years of age (inclusive)
- Confirmed diagnosis of sickle cell disease by hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) [performed locally]. All sickle cell disease genotypes are eligible.
- Experienced at least 1 VOC within the preceding 12 months prior to Screening, as determined by medical history.
- If receiving HU/HC or erythropoietin stimulating agent, must have been receiving the drug for at least 6 months prior to Screening
- Study admission chest X-ray with no acute pathologic processes.
- Hemoglobin >4.0 g/dL. Absolute neutrophil count ≥1.0 x 109/L and platelet count ≥75 x 109/L
- Adequate renal and hepatic function as defined:
- GFR ≥45 mL/min/1.73 m2 calculated by CKD-EPI
- ALT ≤3 x ULN
- Direct (conjugated) bilirubin ≤2 x ULN
- ECOG performance status ≤2
- Written informed consent prior to any screening procedures
- History of stem cell transplant.
- Acute VOC within 15 days or ongoing hospitalization prior to Screening
- Received blood products within 30 days to first dosing
- Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes)
- History of severe hypersensitivity reactions to other monoclonal antibodies
- Received a monoclonal antibody or immunoglobulin -based agent within 1 year of Screening, or has documented immunogenicity to a prior biologic.
- Received active treatment on another investigational trial within 30 days (or 5 half-lives of that agent, whichever is greater) prior to Screening
- Significant active infection or immune deficiency (including chronic use of immunosuppressive drugs)
- Resting QTcF ≥470 msec at pretreatment (baseline) or other cardiac or cardiac repolarization abnormality
Other protocol-defined Inclusion/Exclusion criteria may apply.
- Phase 2
- Study Type
- Intervention Model
- Single Group Assignment
- Primary Purpose
- None (Open Label)
crizanlizumab 5 mg/kg
|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion.||
- NCT ID
- Novartis Pharmaceuticals
Study ContactNovartis Pharmaceuticals